Overview

• In the multinational BaxHTN study of nearly 800 patients, baxdrostat lowered seated systolic blood pressure by about 9–10 mm Hg more than placebo at 12 weeks.
• Roughly 40% of participants on baxdrostat achieved systolic readings below 130 mm Hg versus 18.7% with placebo.
• An ambulatory monitoring substudy showed larger effects over 24 hours, with mean reductions of about 13.7–16 mm Hg and a night-time systolic average about 11.7 mm Hg lower than placebo.
• Baxdrostat, an aldosterone synthase inhibitor, targets hormone overproduction that drives resistant hypertension and was described by investigators as a potential game-changer.
• Safety signals were manageable, with potassium >6 mmol/L in 2.3% (1 mg) and 3% (2 mg) vs 0.4% on placebo and mild hyponatremia in about 19–23% vs 7% on placebo, with few interventions required.